Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer.
Si-Yang LiuTatiana ErazoJustin JeeAndrea ArfeAvantika GuptaLuke R G PikeFernando C SantiniBobby DalyAdam SchoenfeldJordan EichholzKaylie JohnsonAndres MartinezJane SuiNadeem RiazJason ChangSoo-Ryum YangWilliam TravisMaria E ArcilaJiannan GuoEric GagneKavita GargFrederick BaehnerNancy Y LeeAlexander DrilonMark G KrisHoward I ScherPedram RazaviDaniel R GomezDavid R JonesCharles M RudinSarat ChandarlapatyJames M IsbellBob T LiPublished in: European journal of cancer (Oxford, England : 1990) (2024)
Chemoimmunotherapy remains a major treatment option for metastatic HER2-mutant NSCLC. ctDNA can rapidly detect HER2 and co-mutations, and it has the potential to guide and monitor optimal first-line therapy. As a negative prognostic biomarker, detectable ctDNA at baseline would need to be taken into account for patient selection in future studies.